AstraZeneca plc (LON:AZN) had its price target increased by HSBC Holdings plc from GBX 4,150 ($54.58) to GBX 4,340 ($57.08) in a research report released on Wednesday, November 1st. They currently have a reduce rating on the biopharmaceutical company’s stock.
AZN has been the topic of several other research reports. Liberum Capital restated a buy rating and set a GBX 4,800 ($63.13) price target on shares of AstraZeneca plc in a report on Tuesday, September 5th. UBS AG set a GBX 4,550 ($59.84) price objective on AstraZeneca plc and gave the company a neutral rating in a research report on Monday, October 23rd. Jefferies Group LLC upped their price objective on AstraZeneca plc from GBX 4,350 ($57.21) to GBX 4,800 ($63.13) and gave the company a hold rating in a research report on Monday, September 11th. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 5,600 ($73.66) price objective on shares of AstraZeneca plc in a research report on Wednesday, October 11th. Finally, Shore Capital reissued a hold rating on shares of AstraZeneca plc in a research report on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of GBX 5,247.18 ($69.01).
Shares of AstraZeneca plc (LON AZN) traded up GBX 57.50 ($0.76) on Wednesday, hitting GBX 4,927.50 ($64.81). The stock had a trading volume of 1,037,352 shares, compared to its average volume of 1,940,000. AstraZeneca plc has a twelve month low of GBX 3,996 ($52.56) and a twelve month high of GBX 5,520 ($72.60).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.